Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.

In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. 

The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

Cystic Fibrosis Foundation

Cystic Fibrosis Trust

Imperial Innovations

IP Group

Epidarex Capital

Forbion Capital Partners

Novartis Venture Fund

Versant Ventures

Enterprise Therapeutics

#CysticFibrosis affects over 10,800 people in the UK, with one in 25 of us carrying the #gene #mutation that causes it, often without knowing.

Join us for #CFWeek to raise awareness and celebrate the #innovative progress that the #scientific community has already made in #CF #research, #drugdiscovery and #drugdevelopment, as well as the exciting breakthroughs on the horizon.

You can get involved with Cystic Fibrosis Trust here: https://rb.gy/li8ux 
#CysticFibrosisAwareness

What is the importance of endpoints in #raredisease #research?
 
In conversation with International Clinical Trials (Samedan Ltd), our CMO, Dr Niyati Prasad shares her insight on conducting #clinicaltrials for rare diseases, from how #researchers can best select primary and secondary endpoints to the role of ePROs.
 
Read the full interview here: https://bit.ly/3C6hZ0p

Every May, the #cysticfibrosis community comes together for #CFAwarenessMonth, with the unified aim to raise #disease awareness and find a cure for all people with #CF.

Joining this mission, Enterprise Therapeutics is dedicated to the #research, development, and delivery of novel muco-regulatory treatments for CF and other #respiratorydiseases. 

Learn more about our approach here: https://bit.ly/3o6E2An

Our Chief #Medical Officer, Dr Niyati Prasad, is presenting at #Clinical #Outsourcing Group UK.
 
Join Niyati to hear key insights on identifying accurate endpoints to improve clinical study design for #rarediseases.
 
Learn more and register here: https://bit.ly/3X0Wh6P #COGUK

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. They are focused on developing new medicines to treat patients with respiratory diseases such as cystic fibrosis, asthma, and COPD, aiming to improve patient quality of life and reduce the frequency of lung infections.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jan 30, 2024 8:19 PM	d0595de3
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ENTERPRISETHERAPEUTICS

Enterprise Therapeutics